CARCINOID

For Metastatic Carcinoid Tumor
CEPO906A2212: An open-label, phase-IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid tumor
Sponsor: Novartis Pharmacuticals
Principal Investigator: Dr. Scott Wadler
0702-334

[Clinical Trials Home Page] [Breast] [Carcinoid] [Colorectal and Anal] [Gastric] [Genitourinary] [Gynecologic] [Health Outcomes] [Leukemia] [Liver] [Lymphoma] [Melanoma] [Myeloma] [Pancreatic] [Prostate] [Respiratory] [Sarcomas] [Solid Tumors] [Transplant-Related]